Stock Track | Rigel Pharmaceuticals Soars 26.85% on Strong Q3 Results, Raised 2025 Guidance, and Analyst Upgrade

Stock Track11-05

Shares of Rigel Pharmaceuticals (RIGL) are skyrocketing in pre-market trading, surging 26.85% following the release of impressive third-quarter results and an upgrade to its full-year guidance. The biopharmaceutical company's strong performance has ignited investor enthusiasm and prompted an analyst upgrade.

Rigel reported total revenue of $69.5 million for Q3 2025, significantly beating analyst expectations of $61.9 million. The company's net product sales showed remarkable growth, increasing by 65% year-over-year to reach $64.1 million. This growth was primarily fueled by strong performances from key products TAVALISSE, GAVRETO, and REZLIDHIA. Additionally, Rigel's net income for the quarter rose to $27.9 million, more than doubling from $12.4 million in the same period last year.

In light of these strong results, Rigel has raised its full-year 2025 revenue guidance. The company now expects total revenue to be between $285 million and $290 million, up from the previous forecast of $270-$280 million. This positive outlook, coupled with the company's progress in its R289 study for lower-risk MDS, has bolstered investor confidence in Rigel's growth trajectory. Furthermore, Cantor Fitzgerald has raised its price target on Rigel Pharmaceuticals to $38 from $32, while maintaining a Neutral rating on the shares, adding to the positive sentiment surrounding the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166992581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 23:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166992581","market":"sg","top_or_hot":-1,"title":"Stock Track | Rigel Pharmaceuticals Soars 26.85% on Strong Q3 Results, Raised 2025 Guidance, and Analyst Upgrade","media":"Stock Track","content":"<p>Shares of Rigel Pharmaceuticals (RIGL) are skyrocketing in pre-market trading, surging 26.85% following the release of impressive third-quarter results and an upgrade to its full-year guidance. The biopharmaceutical company's strong performance has ignited investor enthusiasm and prompted an analyst upgrade.</p>\n\n<p>Rigel reported total revenue of $69.5 million for Q3 2025, significantly beating analyst expectations of $61.9 million. The company's net product sales showed remarkable growth, increasing by 65% year-over-year to reach $64.1 million. This growth was primarily fueled by strong performances from key products TAVALISSE, GAVRETO, and REZLIDHIA. Additionally, Rigel's net income for the quarter rose to $27.9 million, more than doubling from $12.4 million in the same period last year.</p>\n\n<p>In light of these strong results, Rigel has raised its full-year 2025 revenue guidance. The company now expects total revenue to be between $285 million and $290 million, up from the previous forecast of $270-$280 million. This positive outlook, coupled with the company's progress in its R289 study for lower-risk MDS, has bolstered investor confidence in Rigel's growth trajectory. Furthermore, Cantor Fitzgerald has raised its price target on Rigel Pharmaceuticals to $38 from $32, while maintaining a Neutral rating on the shares, adding to the positive sentiment surrounding the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Rigel Pharmaceuticals Soars 26.85% on Strong Q3 Results, Raised 2025 Guidance, and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Rigel Pharmaceuticals Soars 26.85% on Strong Q3 Results, Raised 2025 Guidance, and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rigel Pharmaceuticals (RIGL) are skyrocketing in pre-market trading, surging 26.85% following the release of impressive third-quarter results and an upgrade to its full-year guidance. The biopharmaceutical company's strong performance has ignited investor enthusiasm and prompted an analyst upgrade.</p>\n\n<p>Rigel reported total revenue of $69.5 million for Q3 2025, significantly beating analyst expectations of $61.9 million. The company's net product sales showed remarkable growth, increasing by 65% year-over-year to reach $64.1 million. This growth was primarily fueled by strong performances from key products TAVALISSE, GAVRETO, and REZLIDHIA. Additionally, Rigel's net income for the quarter rose to $27.9 million, more than doubling from $12.4 million in the same period last year.</p>\n\n<p>In light of these strong results, Rigel has raised its full-year 2025 revenue guidance. The company now expects total revenue to be between $285 million and $290 million, up from the previous forecast of $270-$280 million. This positive outlook, coupled with the company's progress in its R289 study for lower-risk MDS, has bolstered investor confidence in Rigel's growth trajectory. Furthermore, Cantor Fitzgerald has raised its price target on Rigel Pharmaceuticals to $38 from $32, while maintaining a Neutral rating on the shares, adding to the positive sentiment surrounding the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RIGL","symbol_name":"Rigel Pharmaceuticals","start_time":0,"source_url":"","article_id":"1166992581","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166992581","pubTimestamp":1762355602,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Rigel Pharmaceuticals (RIGL) are skyrocketing in pre-market trading, surging 26.85% following the release of impressive third-quarter results and an upgrade to its full-year guidance. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RIGL":"Rigel Pharmaceuticals"},"translate_title":"个股赛道|Rigel Pharmaceuticals因强劲的第三季度业绩、上调2025年指引和分析师升级而飙升26.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RIGL":1},"content_text":"Shares of Rigel Pharmaceuticals (RIGL) are skyrocketing in pre-market trading, surging 26.85% following the release of impressive third-quarter results and an upgrade to its full-year guidance. The biopharmaceutical company's strong performance has ignited investor enthusiasm and prompted an analyst upgrade.\nRigel reported total revenue of $69.5 million for Q3 2025, significantly beating analyst expectations of $61.9 million. The company's net product sales showed remarkable growth, increasing by 65% year-over-year to reach $64.1 million. This growth was primarily fueled by strong performances from key products TAVALISSE, GAVRETO, and REZLIDHIA. Additionally, Rigel's net income for the quarter rose to $27.9 million, more than doubling from $12.4 million in the same period last year.\nIn light of these strong results, Rigel has raised its full-year 2025 revenue guidance. The company now expects total revenue to be between $285 million and $290 million, up from the previous forecast of $270-$280 million. This positive outlook, coupled with the company's progress in its R289 study for lower-risk MDS, has bolstered investor confidence in Rigel's growth trajectory. Furthermore, Cantor Fitzgerald has raised its price target on Rigel Pharmaceuticals to $38 from $32, while maintaining a Neutral rating on the shares, adding to the positive sentiment surrounding the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166992581","isCrawlerRequest":true}